A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD).

By C. O’Mahony, F. Jichi, M. Pavlou, L. Monserrat, A. Anastasakis, C. Rapezzi, E. Biagini, J. Gimeno, G. Limongelli, W. McKenna and 2 more. European Heart Journal, 2014

1,111 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine

View Paper: https://www.semanticscholar.org/paper/7b7682f16d88bc76f36f5cc7687ea81a8822b817

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. B. Maron
2. Steve R. Ommen
3. M. Maron
4. P. Spirito
5. C. Semsarian
6. Iacopo Olivotto

Citations in the corpus

• Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. (2014, background): “Disease features, such as marked LV outflow obstruction at rest or diffuse LVH with wall thickness approaching 30 mm (27,32,33), can serve as “gray zone modifiers” or arbitrators for ICD decision making on a case-by-case basis when assessment is ambiguous using conventional markers.”
• 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the preventionof sudden cardiac death (2015, neutral): “81%, respectively.(364,365) Other major causes of cardiovascular death are HF, thromboembolism and AV block.”